Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperform and raises the price target from $7 to $12.
Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperform and raises the price target from $7 to $12.